_version_ 1783647200893468672
author Morales-Ortega, Alejandro
Rivas-Prado, Luis
Frutos-Pérez, Begoña
Jaenes-Barrios, Beatriz
Farfán-Sedano, Ana Isabel
García-Parra, Carlos Javier
Hernández-Muniesa, Belén
Duarte-Millán, Miguel Ángel
Madroñal-Cerezo, Elena
Ontañón-Nasarre, Ana
Ruiz-Giardín, José Manuel
Bermejo, Fernando
García-Gil, Mario
Gonzalo-Pascua, Sonia
San Martín-López, Juan Víctor
Bernal-Bello, David
author_facet Morales-Ortega, Alejandro
Rivas-Prado, Luis
Frutos-Pérez, Begoña
Jaenes-Barrios, Beatriz
Farfán-Sedano, Ana Isabel
García-Parra, Carlos Javier
Hernández-Muniesa, Belén
Duarte-Millán, Miguel Ángel
Madroñal-Cerezo, Elena
Ontañón-Nasarre, Ana
Ruiz-Giardín, José Manuel
Bermejo, Fernando
García-Gil, Mario
Gonzalo-Pascua, Sonia
San Martín-López, Juan Víctor
Bernal-Bello, David
author_sort Morales-Ortega, Alejandro
collection PubMed
description [Figure: see text]
format Online
Article
Text
id pubmed-7862035
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78620352021-02-05 Early clinical experience with imatinib in COVID-19: Searching for a dual effect Morales-Ortega, Alejandro Rivas-Prado, Luis Frutos-Pérez, Begoña Jaenes-Barrios, Beatriz Farfán-Sedano, Ana Isabel García-Parra, Carlos Javier Hernández-Muniesa, Belén Duarte-Millán, Miguel Ángel Madroñal-Cerezo, Elena Ontañón-Nasarre, Ana Ruiz-Giardín, José Manuel Bermejo, Fernando García-Gil, Mario Gonzalo-Pascua, Sonia San Martín-López, Juan Víctor Bernal-Bello, David J Infect Letter to the Editor [Figure: see text] The British Infection Association. Published by Elsevier Ltd. 2021-05 2021-02-05 /pmc/articles/PMC7862035/ /pubmed/33549625 http://dx.doi.org/10.1016/j.jinf.2021.02.002 Text en © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Morales-Ortega, Alejandro
Rivas-Prado, Luis
Frutos-Pérez, Begoña
Jaenes-Barrios, Beatriz
Farfán-Sedano, Ana Isabel
García-Parra, Carlos Javier
Hernández-Muniesa, Belén
Duarte-Millán, Miguel Ángel
Madroñal-Cerezo, Elena
Ontañón-Nasarre, Ana
Ruiz-Giardín, José Manuel
Bermejo, Fernando
García-Gil, Mario
Gonzalo-Pascua, Sonia
San Martín-López, Juan Víctor
Bernal-Bello, David
Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title_full Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title_fullStr Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title_full_unstemmed Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title_short Early clinical experience with imatinib in COVID-19: Searching for a dual effect
title_sort early clinical experience with imatinib in covid-19: searching for a dual effect
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862035/
https://www.ncbi.nlm.nih.gov/pubmed/33549625
http://dx.doi.org/10.1016/j.jinf.2021.02.002
work_keys_str_mv AT moralesortegaalejandro earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT rivaspradoluis earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT frutosperezbegona earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT jaenesbarriosbeatriz earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT farfansedanoanaisabel earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT garciaparracarlosjavier earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT hernandezmuniesabelen earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT duartemillanmiguelangel earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT madronalcerezoelena earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT ontanonnasarreana earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT ruizgiardinjosemanuel earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT bermejofernando earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT garciagilmario earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT gonzalopascuasonia earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT sanmartinlopezjuanvictor earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect
AT bernalbellodavid earlyclinicalexperiencewithimatinibincovid19searchingforadualeffect